Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with cabozantinib within its marketing authorisation for untreated advanced or metastatic renal cell carcinoma.
Status In progress
Process STA 2018
ID number 1625

Provisional Schedule

Expected publication 16 June 2021

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
18 June 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma. Please note that following on from information received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late August 2020 when we will write to you about how you can get involved.
23 April 2020 - 22 May 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 October 2018 In progress. DHSC referral received.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance